PepGen (NASDAQ:PEPG) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of PepGen (NASDAQ:PEPG) from a sell rating to a hold rating in a research note released on Saturday morning.

PEPG has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of PepGen in a report on Wednesday, October 8th. Guggenheim reiterated a “buy” rating and set a $6.00 price objective on shares of PepGen in a research note on Wednesday, September 24th. HC Wainwright boosted their target price on shares of PepGen from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday. Stifel Nicolaus upped their target price on shares of PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Finally, Wedbush lifted their price target on shares of PepGen from $7.00 to $9.00 and gave the company an “outperform” rating in a report on Thursday, September 25th. Four investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

PepGen Stock Down 3.1%

PEPG stock opened at $4.74 on Friday. PepGen has a twelve month low of $0.88 and a twelve month high of $6.85. The company has a market cap of $155.47 million, a PE ratio of -1.68 and a beta of 1.95. The business’s 50-day simple moving average is $4.00 and its 200 day simple moving average is $2.28.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.11. On average, equities research analysts anticipate that PepGen will post -2.73 EPS for the current year.

Insider Transactions at PepGen

In other news, major shareholder Science Enterprises Plc Oxford purchased 200,000 shares of PepGen stock in a transaction dated Tuesday, September 30th. The shares were bought at an average cost of $3.20 per share, with a total value of $640,000.00. Following the completion of the transaction, the insider directly owned 4,955,388 shares in the company, valued at $15,857,241.60. This trade represents a 4.21% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On PepGen

Several large investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in shares of PepGen in the first quarter valued at approximately $25,000. ADAR1 Capital Management LLC bought a new stake in shares of PepGen in the 1st quarter valued at about $29,000. Rangeley Capital LLC lifted its position in shares of PepGen by 133.3% in the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock valued at $39,000 after buying an additional 20,000 shares during the last quarter. Marshall Wace LLP bought a new stake in PepGen in the 2nd quarter valued at $44,000. Finally, Burkehill Global Management LP bought a new position in shares of PepGen in the third quarter valued at about $46,000. Institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.